

INVITATION

You are invited to a live educational webcast for healthcare professionals:

2021 INFLUENZA VACCINE AND COVID-19 VACCINE UPDATE

Please join us February 24th 2021, when we launch FLUCELVAX[®] QUAD, the first cell-based influenza vaccine available in Australia. This live webcast will also provide an update on COVID-19 vaccines, and will feature three key speakers:

Dr Russell Bassar,

Senior Vice President, Research & Development, will discuss Seqirus' commitment to innovation and the development of influenza vaccine cell technology.

Prof. Robert Booy,

Infectious diseases and immunisation expert, outlines the clinical profile of FLUCELVAX[®] QUAD.

Dr Jonathan Anderson,

Head of Seqirus Medical Affairs, Asia Pacific, discusses the 2020 & 2021 influenza seasons, and provides an update on COVID-19 vaccines.

DATE:

**Wednesday,
February 24th 2021**

TIME:

6:30 PM AEST

Online meeting room opens 30 mins prior

AGENDA:

6:00 PM Online meeting room opens

6:30 PM Welcome and Introduction

6:35 PM Presentations

7:35 PM Q&A

8:00 PM Close

Register at www.whatsnewflu.com.au

Access code: **FLU221**

I hope you are able to join us for a live educational webcast.

Regards,

Jan Grimmer, Representative,

E: jan.grimmer@seqirus.com

P: 0434 608 048

This session is proudly presented by



FLUCELVAX[®]
QUAD

Quadrivalent influenza vaccine (surface antigen, inactivated, prepared in cell cultures)

INVITATION

2021 INFLUENZA VACCINE AND COVID-19 VACCINE UPDATE

Please join us February 24th 2021, when we launch FLUCELVAX® QUAD, the first cell-based influenza vaccine available in Australia.¹

This live webcast will also provide an update on COVID-19 vaccines, and will feature three key speakers. See over for details.

CELL-BASED
FLU VACCINE
APPROVED FOR PATIENTS

[9]+
YEARS¹

The first and only cell-based influenza vaccine available in Australia¹

FLUCELVAX®
QUAD

Quadrivalent influenza vaccine (surface antigen, inactivated, prepared in cell cultures)

Register at www.whatsnewflu.com.au Access code: **FLU221**

Representative: Jan Grimmer

Email: jan.grimmer@seqirus.com

Phone: 0434 608 048

PBS Information: This product is not listed on the National Immunisation Program (NIP) or the PBS.

Before prescribing, please review Product Information available at www.seqirus.com.au/products or via Seqirus Medical Information 1800 642 865.

MINIMUM PRODUCT INFORMATION Flucelvax® Quad (Inactivated Quadrivalent Influenza Vaccine (prepared in cell cultures)) - Suspension for injection. **Indication:** For the prevention of influenza caused by Influenza Virus, Types A and B contained in the vaccine, for use in adults and children 9 years of age and older. **Contraindications:** Individuals with known severe allergic reactions (e.g. anaphylaxis) to any component of the vaccine or to a previous dose of any influenza vaccine. **Precautions:** Treatment and supervision for anaphylactic reactions should be available. Antibody response in immunocompromised patients may be lower. Careful consideration for use in history of Guillain-Barré syndrome within 6 weeks of previous influenza vaccination. Postpone immunisation in patients with febrile illness or acute infection. A protective immune response may not be elicited in all vaccine recipients. **Use in Pregnancy (Category B1):** The safety of Flucelvax® Quad in pregnancy has not been assessed in clinical trials. There are no reproductive and developmental toxicity studies with Flucelvax® Quad. Reproductive and developmental toxicity data from cell-based trivalent influenza vaccine (TIVc) do not predict an increased risk of developmental abnormalities. **Use in Lactation:** Not been evaluated in nursing mothers. **Interactions:** No data available on co-administration with other vaccines. Based on clinical experience TIVc, Flucelvax® Quad can be given at the same time as other vaccines (in separate limbs) (adverse reactions may be intensified). **Adverse Effects:** Local - pain, erythema. Systemic - headache, fatigue, upper respiratory tract infection, nasopharyngitis (See full PI). **Dosage and Administration:** Intramuscular injection only: single 0.5mL dose. **Presentation:** 0.5mL single-use syringe. **Storage:** Store at 2°C to 8°C; must not be frozen; protect from light. Based on Approved Product Information.

Reference: 1. FLUCELVAX® QUAD Approved Product Information.

Seqirus abides by the Medicines Australia Code of Conduct, only invitees may attend this event. Any costs (e.g. travel or meals) incurred by a partner/spouse, guest or family member travelling with a healthcare professional attending this event cannot be paid for or subsidised by Seqirus. Attendees are responsible for obtaining approval to receive and/or disclose hospitality as required by their employer or professional association.

Opt-out statement: If you do not wish to receive further information about Seqirus educational events or Seqirus products and services, please email SeqirusAU.SalesSupport@seqirus.com

Seqirus (Australia) Pty Ltd Melbourne, Victoria. ABN: 66 120 398 067. www.seqirus.com.au. Seqirus Medical Information: 1800 642 865. FLUCELVAX® is a registered trademark of Seqirus UK or its affiliates. Seqirus™ is a trademark of Seqirus UK Limited or its affiliates. Date of preparation: December 2020. SEQ/XQIV/1120/0119.


A CSL COMPANY